Health

#SFHS2612595AFrance Adds ZADENVI to the Reimbursable Medicines List for Specific Osteoporosis Treatment

🇫🇷France··Other·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

ZADENVI 60 mg, a denosumab injectable medicine, becomes reimbursable by French health insurance for a narrow osteoporosis use: post-menopausal women at high fracture risk, only as a second-line treatment after bisphosphonates. Coverage is limited to patients meeting specific fracture-risk criteria. The first prescription must come from a specialist involved in osteoporosis care, such as a rheumatologist, gynecologist, geriatrician, or internist.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Adds ZADENVI 60 mg denosumab injectable solution to the list of medicines reimbursed by French health insurance
  • Limits reimbursement to post-menopausal osteoporosis patients at high fracture risk after bisphosphonate treatment
  • Requires the initial prescription to be issued by a specialist involved in osteoporosis care

Obligations

What this law requires

high

Reimbursement of ZADENVI 60 mg must be limited to treatment of post-menopausal osteoporosis in women at high risk of fracture, and only as second-line therapy following bisphosphonate treatment.

French health insurance reimbursement bodieshealthcare providers prescribing reimbursable medicines
Applies from the fourth day after publication in the Journal officiel de la République française
operational
high

Patients may be treated as high fracture risk for reimbursement only if they have had a fragility fracture, or if they meet the specified bone-density and additional-risk-factor criteria.

healthcare providers prescribing reimbursable medicinesFrench health insurance reimbursement bodies
Applies from the fourth day after publication in the Journal officiel de la République française
operational
medium

In the absence of a fragility fracture, reimbursement eligibility must be limited to women with T-score below -3, or T-score at or below -2.5 combined with other fracture risk factors such as age over 60, systemic corticosteroid therapy of at least 7.5 mg/day prednisone equivalent, BMI below 19 kg/m2, first-degree maternal history of femoral neck fracture, or menopause before age 40.

healthcare providers prescribing reimbursable medicinesFrench health insurance reimbursement bodies
Applies from the fourth day after publication in the Journal officiel de la République française
operational
high

The initial prescription for reimbursable ZADENVI 60 mg must be made by a specialist involved in osteoporosis care, such as a rheumatologist, gynecologist, geriatrician, or internist.

healthcare providers prescribing reimbursable medicinesspecialist physicians involved in osteoporosis care
Applies from the fourth day after publication in the Journal officiel de la République française
operational

Affected Parties

Post-menopausal women with high fracture riskOsteoporosis specialists+2 more…

Tags

pharmaceutical reimbursement,osteoporosis,denosumab